|
RESEARCH AND LICENSE AGREEMENT (Details Textual) (USD $)
In Thousands, except Share data, unless otherwise specified
|
1 Months Ended |
9 Months Ended |
12 Months Ended |
|
Feb. 28, 2011
|
Jan. 31, 2011
|
Dec. 24, 2009
|
Sep. 30, 2013
|
Dec. 31, 2009
|
| Research License Agreement Expenses Paid |
|
|
$ 400 |
|
|
| Obligation Amount To Fund Extended Research Period |
|
|
|
|
1,140 |
| Research and Development Expenses Reversed |
|
|
|
|
760 |
| Research License Interest Rate |
|
|
|
|
32 |
| Shares Granted As Per Research And License Agreement |
|
|
|
|
1,120,000 |
| Selling Of Shares Term |
|
|
|
|
185 days |
| Stock Based Compensation Related To Shares Granted Under Research License Agreement |
|
|
|
|
51 |
| Number Of Shares Sold By Purchaser As Permitted By Settlement Agreement |
|
167,530 |
|
|
|
| Proceeds From Shares Sold By Purchaser As Permitted By Settlement Agreement |
|
35 |
|
|
|
| Value Of Shares Granted To Purchaser As Per Research and License Agreement |
|
235 |
|
|
|
| Research License Payments Made As Per Settlement Agreement |
5 |
|
|
|
|
| Proceeds From Shares Issued |
|
|
|
|
Company would pay to Ramot the difference between the proceeds that Ramot has received from sales of the shares up to such date together with the September Payment (if any) that has been transferred to Ramot up to such date, and $240. |
| Percentage Of Royalty Payment If Licensed Product Covered By Valid Claim Or Orphan Drug Status |
|
|
|
5.00% |
|
| Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status |
|
|
|
3.00% |
|
| Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status |
|
|
|
15 years |
|
|
Initial Research Period [Member]
|
|
|
|
|
|
| Research License Liability |
|
|
240 |
|
|
|
Extended Research Period [Member]
|
|
|
|
|
|
| Research License Liability |
|
|
$ 380 |
|
|